<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488928</url>
  </required_header>
  <id_info>
    <org_study_id>2015-1676</org_study_id>
    <nct_id>NCT02488928</nct_id>
  </id_info>
  <brief_title>E- Predict: EBUS ELASTOGRAPHY STRAIN in Lung Cancer</brief_title>
  <acronym>E-PREDICT</acronym>
  <official_title>E-PREDICT Evaluating the Predictive Value of EBUS ELASTOGRAPHY STRAIN in Patients With (Suspected) Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EBUS elastography is a method to determine stiffness of lymph nodes, based on the minute
      deformation of the node by the beating heart. Whether EBUS elastography may further increase
      the sensitivity to predict the presence or absence of malignancy is unclear.

      We suggest to use EBUS elastography strain pattern analysis for this assessment and correlate
      these measurements with the final pathology outcome to determine NPV, PPV, sensitivity and
      specificity of this analysis to predict the presence or absence of malignancy in patients
      with (suspected) lung cancer in a prospectively obtained observational cohort study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will undergo a routine EBUS and/or EUS or EUSb with Pentax series EBUS or EUS scopes
      in combination with Hitachi Preirus Hi-Vision ultrasound processor with installed
      elastography software. Normal international guidelines for staging, diagnosis and specimen
      acquisition will be followed. For a normal evaluation B-mode measurements from all lymph node
      regions are obtained assessing size and standard ultrasound characteristics and all lymph
      nodes in the regions of interest that meet the criteria for fine needle aspiration will be
      sampled. For this study, in addition to the normal B-mode assessment of five sonographic
      B-mode characteristics elastography strain graph video, elastography image, and a strain
      histogram from the region of interest will be obtained.

      Fine needle aspiration for cytology evaluation will be obtained from nodes based on imaging
      characteristics or standard sonography characteristics following current everyday clinical
      practice and the international guidelines. Subsequently, the patient charts will be
      retrospectively analysed after completion of the diagnostic and/or surgical treatment of the
      (suspected) lung cancer to match the obtained imaging data to pathology results (cytology and
      or histology where present) and clinical follow up until 6 months after the diagnostic
      procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>stiffness of lymph nodes</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 4 hours</time_frame>
    <description>stiffness/strain is a relative measure and has therefor no units</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with suspected or proven lung cancer are eligible if there is an indication for
        EBUS, EUS or combined EBUS and EUSb (single scope, EUS with EBUS scope). Eligible are
        patients with no contra-indications for EBUS.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with indication for diagnostic or staging EBUS procedure for suspected or
             proven lung cancer.

          -  ASA physical status 1-3.

          -  Age 18 years or older.

        Exclusion Criteria:

          -  Bleeding disorders.

          -  Contra-indication for temporary interruption of the use of anticoagulant therapy
             (acenocoumarol, warfarin, therapeutic dose of low molecular weight heparines or
             clopidrogel).

          -  Known allergy for lidocaine.

          -  Uncontrolled pulmonary hypertension.

          -  Recent and/or uncontrolled cardiac disease.

          -  Compromised upper airway (eg concomitant head and neck cancer or central airway
             stenosis for any reason).

          -  Prior radiotherapy treatment involving the central airways

          -  ASA classification greater than or equal to 4.

          -  Pregnancy.

          -  Inability to consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik van der Heijden, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>chest physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik van der Heijden, MD, PhD</last_name>
    <phone>0031243610325</phone>
    <email>Erik.vanderHeijden@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Garms</last_name>
    <phone>0031243617354</phone>
    <email>Linda.Garms@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>Dk 2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Krasnik, MD</last_name>
      <email>mark.krasnik@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Interventional Pulmonology Unit Policlinico S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocco Trisolini, MD</last_name>
      <phone>39 (347) 4251647</phone>
      <email>rocco.trisolini@aosp.bo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michela Bezzi, MD</last_name>
      <phone>055 794 7200</phone>
      <email>drmichela.bezzi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Fausto Leoncini, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ausl Modena - Ospedale Santa Maria Bianca</name>
      <address>
        <city>Modena</city>
        <zip>41037</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Messi, MD</last_name>
      <phone>0535 602289</phone>
      <email>a.messi@ausl.mo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pesaro-Fano Hospital</name>
      <address>
        <city>Pesaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piero Candoli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>RadboudUMC</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik van der Heijden, MD, PhD</last_name>
      <phone>+31243610325</phone>
      <email>Erik.vanderHeijden@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>L Garms</last_name>
      <phone>+31243617354</phone>
      <email>Linda.Garms@radboudumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Erik HF van der Heijden, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jouke Annema, MD</last_name>
      <phone>31- 20-566 4356</phone>
      <email>j.t.annema@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Laurence Crombag, MD</last_name>
      <phone>31- 20-566 4356</phone>
      <email>l.m.crombag@amc.uva.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>EBUS</keyword>
  <keyword>elastography</keyword>
  <keyword>predictive value</keyword>
  <keyword>strain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

